Search Results
15 protocol(s) meet the specified criteria
100229Not Open *
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Phase II Study of Regn2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

102346Not Open *
Phase II Neoadjuvant Trial of Nivolumab in Combination with HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1A Melanoma (Neo-NivoHF10)

Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab

Assessing Tissue Remodeling in the Skin using Skin Fluorescence Imaging (SFI)

117626Not Open *
Phase II Study of Combining Talimogene Laherparepvec (T-VEC) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy

55911Not Open *
Multicenter, Double-Blind, Placebo-Controlled, Adaptive Phase III Trial of POL-103A Polyvalent Melanoma Vaccine in Post-Resection Melanoma Patients with a High Risk of Recurrence

Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec

Randomized, Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma

Prospective, Randomized, Blinded, Placebo-Controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) plus Yeast Cell Wall Particles (YCWP) plus Dendritic Cells (DC) Vaccine versus Unloaded YCWP plus DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence

81405Not Open *
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

Phase IB Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

Phase IB, Open-Label, Multicenter, Dose-Escalation Trial of Intratumoral Injections of SD-101 in Combination with Pembrolizumab in Patients with Metastatic Melanoma

Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)